Actively Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Led by Rigshospitalet, Denmark · Updated on 2022-12-12
2000
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the DYNAMITE trial (Dynamic CT stress myocardial perfusion, CT fractional flow reserve (FFR-CT) and coronary CT angiography for optimized treatment strategy in patients with chest pain syndromes) is to determine the ability of combined anatomical and functional cardiac CT imaging to improve morbidity and mortality in patients with suspected or known ischemic heart disease.
CONDITIONS
Official Title
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Who Can Participate
Eligibility Criteria
You may qualify if you...
-
Chest pain in patients with clinically suspected or confirmed ischemic heart disease
-
Clinical indication for non-acute coronary evaluation
-
Status of coronary revascularization
-
With previous coronary revascularization - all patients
-
Without previous coronary revascularization
-
Age≥65 years - all patients with chest pain
-
Age>50 - <65 years - typical angina pectoris and at least one cardiovascular risk factor and/or previous myocardial infarction
- Typical angina requiring all 3 criteria present: a) constrictive discomfort in the front of the chest or in the neck, jaw, shoulder or arm, b) precipitated by physical exertion c) relieved by rest or nitrates within 5 min.
- Cardiovascular risk factors: hypertension, diabetes, hypercholesterolemia, current smoking, family history of ischemic heart disease, previous stroke, peripheral artery disease
-
-
You will not qualify if you...
- Persistent chest pain and signs of ongoing acute myocardial ischemia requiring acute coronary intervention
- Hospitalization and discharge with the confirmed diagnosis acute coronary syndrome (STEMI or NSTEMI) within the last 6 months
- Severe valvular heart disease as primary diagnosis and/or in potential need of percutaneous or surgical valve treatment
- Known severe heart failure (LVEF less than 35%)
- Language, cultural or mental factors preventing the patient from understanding the informed consent form
- Known atrial fibrillation
- Known renal impairment (estimated Glomerular Filtration Rate below <30 ml/min)
- Known x-ray contrast allergy
- Known intolerance to adenosine infusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Cardiology and Radiology, Rigshospitalet, The Heart Center, Capital Region of Copenhagen, University of Copenhagen
Copenhagen, Denmark, 2100
Actively Recruiting
Research Team
K
Klaus F Kofoed, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here